2 ratings / 4.5 average

Acute Leukemia

Garcia-Manero G, Gore SD, Cogle C et al.

University of Texas M D Anderson Cancer Center, Houston, TX, USA.

 J Clin Oncol 2011;29:2521–7.

Editor’s note: Azacitidine is a DNA hypomethylating agent that has shown considerable efficacy in patients with myelodysplasia (MDS). Data suggest that chronic exposure to azacitidine over several cycles is necessary for therapeutic effect. This is complicated as the agent is currently administered by subcutaneous injection daily over several days per cycle, and patients who require treatment are often elderly.

Return to top

LATEST ARTICLES